MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

Paul Klimo, J. M. Connors

Research output: Contribution to journalArticle

573 Citations (Scopus)

Abstract

Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), an innovative pilot chemotherapy program emphasizing weekly treatment, antibiotic prophylaxis, daily corticosteroid treatments, and brief duration (12 weeks). Fifty-one patients (84%) achieved a complete response and 10 patients (16%) had a partial response. Over a median follow-up after treatment of 23 months, the actuarial overall survival for the entire group has been 76%; for complete responders the relapse-free survival had been 90%. Toxicity was modest with one treatment-related death and seven episodes of serious infection. The most frequent toxicity was mucositis. Thus, MACOP-B is an effective treatment for large-cell lymphoma that can be delivered in 12 weeks with an acceptable incidence of toxicity. This regimen can achieve results similar and possibly superior to those of other presently used regimens of longer duration.

Original languageEnglish (US)
Pages (from-to)596-602
Number of pages7
JournalAnnals of Internal Medicine
Volume102
Issue number5
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Therapeutics
Mucositis
Survival
Antibiotic Prophylaxis
Leucovorin
Bleomycin
Vincristine
Prednisone
Methotrexate
Doxorubicin
Cyclophosphamide
Lymphoma
Adrenal Cortex Hormones
Recurrence
Incidence
Infection

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. / Klimo, Paul; Connors, J. M.

In: Annals of Internal Medicine, Vol. 102, No. 5, 01.01.1985, p. 596-602.

Research output: Contribution to journalArticle

@article{f0419d17547945e9ae0f7091c41009b0,
title = "MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma",
abstract = "Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), an innovative pilot chemotherapy program emphasizing weekly treatment, antibiotic prophylaxis, daily corticosteroid treatments, and brief duration (12 weeks). Fifty-one patients (84{\%}) achieved a complete response and 10 patients (16{\%}) had a partial response. Over a median follow-up after treatment of 23 months, the actuarial overall survival for the entire group has been 76{\%}; for complete responders the relapse-free survival had been 90{\%}. Toxicity was modest with one treatment-related death and seven episodes of serious infection. The most frequent toxicity was mucositis. Thus, MACOP-B is an effective treatment for large-cell lymphoma that can be delivered in 12 weeks with an acceptable incidence of toxicity. This regimen can achieve results similar and possibly superior to those of other presently used regimens of longer duration.",
author = "Paul Klimo and Connors, {J. M.}",
year = "1985",
month = "1",
day = "1",
doi = "10.7326/0003-4819-102-5-596",
language = "English (US)",
volume = "102",
pages = "596--602",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

AU - Klimo, Paul

AU - Connors, J. M.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), an innovative pilot chemotherapy program emphasizing weekly treatment, antibiotic prophylaxis, daily corticosteroid treatments, and brief duration (12 weeks). Fifty-one patients (84%) achieved a complete response and 10 patients (16%) had a partial response. Over a median follow-up after treatment of 23 months, the actuarial overall survival for the entire group has been 76%; for complete responders the relapse-free survival had been 90%. Toxicity was modest with one treatment-related death and seven episodes of serious infection. The most frequent toxicity was mucositis. Thus, MACOP-B is an effective treatment for large-cell lymphoma that can be delivered in 12 weeks with an acceptable incidence of toxicity. This regimen can achieve results similar and possibly superior to those of other presently used regimens of longer duration.

AB - Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), an innovative pilot chemotherapy program emphasizing weekly treatment, antibiotic prophylaxis, daily corticosteroid treatments, and brief duration (12 weeks). Fifty-one patients (84%) achieved a complete response and 10 patients (16%) had a partial response. Over a median follow-up after treatment of 23 months, the actuarial overall survival for the entire group has been 76%; for complete responders the relapse-free survival had been 90%. Toxicity was modest with one treatment-related death and seven episodes of serious infection. The most frequent toxicity was mucositis. Thus, MACOP-B is an effective treatment for large-cell lymphoma that can be delivered in 12 weeks with an acceptable incidence of toxicity. This regimen can achieve results similar and possibly superior to those of other presently used regimens of longer duration.

UR - http://www.scopus.com/inward/record.url?scp=0021918307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021918307&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-102-5-596

DO - 10.7326/0003-4819-102-5-596

M3 - Article

C2 - 2580468

AN - SCOPUS:0021918307

VL - 102

SP - 596

EP - 602

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -